---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-033086"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:26:02.378290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunome reports Q4 2022 net loss $7.8M; announces AbbVie collaboration with $30M upfront

## Summary
- Net loss of $7.8M ($0.64 per share) for Q4 2022; full-year net loss $36.9M ($3.09 per share).
- Cash and equivalents $20.3M as of Dec 31, 2022.
- Entered strategic collaboration with AbbVie for up to 10 novel antibody-target pairs; $30M upfront plus up to $70M platform milestones.
- Per target: up to $120M in development/commercial milestones, $150M in sales milestones, plus tiered royalties.
- Seeking partner for COVID-19 antibody cocktail IMM-BCP-01 after Phase 1b cohort completed.

## SEC filing metadata
- accession: 0001104659-23-033086
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923033086/0001104659-23-033086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923033086/tm239583d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-033086
- JSON: https://secwatch.observer/filing/0001104659-23-033086.json
- Plain text: https://secwatch.observer/filing/0001104659-23-033086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.